The Role of Biomarker Testing and Appropriate Use of Immune Checkpoint Inhibitors for the Management of Non-Small Cell Lung Cancer

This activity is module 3 of a 4-part webinar curriculum.

Program Description

Assessment of the biomarker programmed death ligand 1 (PD-L1) is integral in the treatment of multiple types of cancer, including non-small cell lung cancer (NSCLC). In patients who are positive for PD-L1, immune checkpoint inhibitor (ICI) therapy may be advantageous. As members of the health care team, pharmacists can assist in selection of biomarker-directed therapies for patients with NSCLC and can also aid in management of ICI adverse effects. This webinar is designed to educate pharmacists on the role of ICI therapy in patients who are PD-L1-positive and will also emphasize strategies for pharmacist involvement in patient care.

Target audience: Oncology pharmacists, specialty pharmacists, and health-system pharmacists

Type of activity: Application
Release date: January 31, 2022
Expiration date: January 31, 2023

Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Classify the role of programmed death ligand 1 biomarker testing in non-small cell lung cancer (NSCLC)
• Analyze the data supporting immune checkpoint inhibitors (ICIs) in the management of NSCLC
• Document important considerations for use of ICIs in patients with NSCLC

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-22-040-H01-P. The activity is available for CE credit through January 31, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the webinar in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Faculty

Shelby Merchant, PharmD, BCOP, has no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Amy Seung, PharmD, BCOP, FHOPA; Meg Taylor, PharmD, CPP; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta have no financial relationships with commercial interests to disclose.

An anonymous peer reviewer has been used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms